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ARTICLE OPEN
The Help for Hay Fever community pharmacy-based pilot
randomised controlled trial for intermittent allergic rhinitis
Sarah Smith1, Terry Porteous1✉, Christine Bond1, Jill Francis2, Amanda J. Lee1, Richard Lowrie3, Graham Scotland1, Aziz Sheikh4,
Mike Thomas 5, Sally Wyke6 and Lorraine Smith7
Management of intermittent allergic rhinitis (IAR) is suboptimal in the UK. An Australian community pharmacy-based intervention
has been shown to help patients better self-manage their IAR. We conducted a pilot cluster RCT in 12 Scottish community
pharmacies to assess transferability of the Australian intervention. Trained staff in intervention pharmacies delivered the
intervention to eligible customers (n= 60). Non-intervention pharmacy participants (n= 65) received usual care. Outcome
measures included effect size of change in the mini-Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ) between baseline,
1-week and 6-week follow-up. Trial procedures were well received by pharmacy staff, and customer satisfaction with the
intervention was high. The standardised effect size for miniRQLQ total score was −0.46 (95% CI, −1.05, 0.13) for all participants and
−0.14 (95% CI,−0.86, 0.57) in the complete case analysis, suggesting a small overall treatment effect in the intervention group. A
full-scale RCT is warranted to fully evaluate the effectiveness of this service.
npj Primary Care Respiratory Medicine           (2020) 30:23 ; https://doi.org/10.1038/s41533-020-0180-4
INTRODUCTION
Intermittent allergic rhinitis (IAR) (also known as seasonal AR or
hay fever) is a major chronic respiratory disease with high UK
prevalence, estimated at 26%1. Prevalence has increased sub-
stantially in recent years2,3. IAR has a significant negative impact
on quality of life (QOL)4, productivity5, school performance6 and
healthcare costs7. People with IAR are also at increased risk of
suffering asthma, rhinosinusitis, and other related upper airway
conditions8,9. Despite availability of evidence-based clinical guide-
lines for managing IAR in primary care, management of the
condition in the UK is suboptimal10–13, suggesting significant
avoidable morbidity.
Recent research in Australia has shown that a community
pharmacist-delivered IAR intervention can improve patient out-
comes14–16. Such an approach could potentially improve IAR
management in the UK and other healthcare systems, as
community pharmacists are well placed to recognise and
recommend treatment for IAR, particularly for intermittent and
mild cases17–19. However, it is unclear whether the IAR interven-
tion will deliver the same benefits outside the Australian setting in
which it was developed. Hence, locally conducted research is
needed to inform policy and practice in other countries. Initially,
estimates of effect sizes, participation rates and completion rates
need to be derived to inform the design of a UK trial20. To our
knowledge, no community pharmacy-based behaviour change
intervention, designed to improve self-management of IAR, has
been undertaken outside Australia.
The aim of this study was to conduct a pilot randomised
controlled trial (RCT) in Scotland of ‘Help for Hay Fever’ (HFHF), a
goal-focussed intervention for the self-management of intermit-
tent IAR based on the Australian programme but adapted for the
UK setting. Specific objectives were to test transferability of
methods and measures of the intervention used in the Australian
research and to inform the design of a future UK full-scale RCT.
The research questions included: whether the pharmacy staff
training programme, study materials and procedures were
acceptable and suitable for use in a UK setting; whether the
intervention was acceptable to pharmacy staff delivering and
customers receiving the service; and whether the outcome
measures were appropriate for quantification of pharmacy and
customer recruitment and completion rates and for estimation of
effect sizes and variability of change in allergic rhinitis-related QOL
to inform a sample size calculation.
RESULTS
Recruitment, retention and completion
Figure 1 shows the flow of participants through the study.
Thirty-one pharmacies agreed to participate (7% of those
approached, n= 31/445). Following randomisation, 12 pharmacies
were recruited and retained, 6 in each arm, i.e. 3 intervention and
3 usual care pharmacies in each participating health board area
(HBA) (Fig. 1).
Seven pharmacists and seven pharmacy assistants from the six
intervention pharmacies (i.e. at least one member of staff from
each pharmacy) attended the 3-h training event. Scores for the
‘before-and-after’ IAR knowledge test improved from 58% of
questions being answered correctly before training to 85%
following training. The evaluation form, completed by all
attendees, showed training was very positively received. Content
and format of the training, confidence of study procedures and
general feedback achieved mean scores ranging from 8.2 to 9.3
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out of 10. The lowest mean score (7.8/10) was for ‘role-playing’ of
the intervention.
Completion of the daily recruitment log (recording numbers
eligible, declined, recruited) was variable. Nonetheless, data from
returned logs, whether fully or partially complete, showed that at
least 288 customers were assessed for eligibility, and of these, 125
(43%) were recruited. Recruitment rates varied across pharmacies
(Table 1).
Participants in both groups were mostly female and comparable
in terms of employment status. Mean age was higher for the
intervention group (43 years) than control (37 years), and Scottish
Index of Multiple Deprivation (SIMD) scores (Supplementary Note
1)21 were lower in the intervention group (i.e. less deprived) (Table 2).
Retention rates for the intervention group at 1 week and
6 weeks were 70% at both timepoints and, for the control group,
65% and 60%, respectively (see Fig. 1). Only 71 customers (57%)
returned questionnaires at all three timepoints.
Quantitative outcome measures
IAR-related QOL values were calculated for both ‘total’ and
‘domain’ scores of the mini-Rhinoconjunctivitis Quality of Life
Questionnaire (miniRQLQ)22. From baseline to 6 weeks, mean
miniRQLQ total score decreased in both groups (usual care group
by 1.00 (SD 1.34); intervention group by 1.45 (SD 1.26)), reflecting
improved QOL for both groups but by slightly more in the
intervention group (Table 3). A sensitivity analysis of only those
respondents who provided complete miniRQLQ data at all three
timepoints (i.e. complete case analysis) showed similar decreases
(usual care group by 1.35 (SD 1.29); intervention group by 1.47
(SD 1.35)).
Table 4 shows the main analysis of adjusted between-treatment
difference in the 6-week mean miniRQLQ by domain and overall.
The standardised effect size for miniRQLQ total score was −0.46
(95% confidence interval (CI), −1.05, 0.13) for all participants and
−0.14 (95% CI, −0.86, 0.57) in the complete case analysis,
suggesting a small overall treatment effect23 in the intervention
group (Table 4). The effect size was, however, greater for the
miniRQLQ domains of practical problems and nose symptoms. The
intra-cluster correlation coefficients (ICCs) were close to zero for
almost all miniRQLQ domains and the total score, indicating a
non-significant effect of clustering by pharmacy (Table 4).
Fig. 1 Flow of participants into the ‘Help for Hay Fever’ trial.
Table 1. Recruitment by pharmacy.
Region Total
Grampian
Pharmacy ID A056 A108 A125 A007 A014 A055
Number of customers
recruited
11 8 13 12 4 13 61
Greater Glasgow
and Clyde
Pharmacy ID G054 G126 G269 G003 G210 G246
Number of customers
recruited
10 15 3 12 10 14 64
Total 125
S Smith et al.
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We found that some pharmacies struggled to recruit 12
customers, therefore, for the purpose of calculating a sample size
for a future RCT, we would assume a conservative ICC of 0.01 and
a cluster (pharmacy) size of four. A sample size of 240 participants
per group would have 90% power to detect a difference in mean
baseline to 6-week change in miniRQLQ of 0.4 (intervention −1.4
and usual care −1.0). This assumes a standard deviation of 1.31
and a 2-sided 5% significance level. Again, based on our data, we
estimate a 40% attrition rate, so a total of 120 pharmacies (60 per
arm) would each need to recruit seven customers to give an
estimated total sample of 840.
It was of interest to examine the proportion of patients who
showed a decrease in miniRQLQ of at least 0.5 scale points
(minimally important within-group change) for each randomisa-
tion group. This proportion was 0.52 for the intervention group
and 0.40 for the usual care group (a difference of 0.12 benefitting
from the goal-focussed intervention and a number needed to
treat of 8.3) (Table 4).
For symptom severity at 1 week (Spector scale)24, an improve-
ment was observed in scores for nasal symptoms (but not for non-
nasal symptoms) in both groups. For medication adherence at
Table 3. Allergic rhinitis quality of life (MiniRQLQ Total Scorea) by
treatment arm across timepoints.
All participants n Usual care n Intervention
Mean SD Mean SD
All participants
Baseline 65 2.71 1.25 60 3.10 1.15
1 week 42 2.26 1.15 42 2.20 1.28
6 weeks 39 1.74 1.18 42 1.43 1.06
Change (W1–B) 42 −0.67 1.17 42 −0.74 1.17
Change (W6–B) 39 −1.00 1.34 42 −1.45 1.26
Complete case analysis
Baseline 26 3.1 1.29 32 2.84 1.23
1 week 26 2.25 0.98 32 2.13 1.37
6 weeks 26 1.75 1.19 32 1.38 1.04
Change (W1–B) 26 −0.85 1.07 32 −0.72 1.15
Change (W6–B) 26 −1.35 1.29 32 −1.47 1.35
W1 1 week, B baseline, W6 6 weeks, SD standard deviation.
aMiniRQLQ mean total scores range from 0 to 6; lower scores reflect better
quality of life.
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Table 2. Baseline patient characteristics.
Characteristic Usual care
(N= 65), n (%)
Intervention
(N= 60), n (%)
Mean age (SD) 36.6 (16.2) 43.0 (15.9)
Male 30 (46.1) 25 (41.7)
SIMDa (quintiles)
Most deprived—1 18 (27.7) 10 (16.7)
2 18 (27.7) 4 (6.7)
3 9 (13.8) 4 (6.7)
4 8 (12.3) 12 (20.0)
Least deprived—5 12 (18.5) 30 (50.0)
Currently employed 49 (75.4) 45 (75.0)
SD standard deviation.
aSIMD—Scottish Index of Multiple Deprivation is a relative measure of
deprivation21.
S Smith et al.
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1 week (Medication Adherence Rating Scale)25, there was
improvement in both groups. Regarding self-efficacy at 1 week
(adapted Lorig scale)26, scores improved slightly in the interven-
tion group but not in the usual care group. Between-group
differences were not statistically significant for any of these three
measures.
Economic analyses
The resource use and associated cost variables used in economic
analysis are summarised by treatment allocation group in Table S1
(Supplementary Note 2). Based on the adjusted analysis, the
intervention was associated with a non-significant increase in
mean (95% CI) costs to the National Health Service (NHS) (+£2.55
(−£5.77 to £10.87) at 6 weeks, for a non-significant improvement
in mean (95% CI) EQ-5D (EuroQoL 5-Dimensions) score (0.019
(−0.0438 to 0.0813)). However, the opposite direction of effect
was observed on the EQ-5D at 1 week (−0.010 (95% CI, −0.080,
0.059); Table 5). Overall, mean (95% CI) costs to society
(incorporating estimated patient costs and indirect productivity
costs) were also non-significantly elevated at 6 weeks (+£7.00
(−£5.84 to £19.84)).
Qualitative analysis
One staff member was interviewed from each of the six
intervention pharmacies (five pharmacists and one pharmacy
assistant). Staff were asked to rate how difficult it was to recruit
participants for the study; four out of six reported a ‘difficulty’
rating of ≥3 (scale range; 1–5). The time needed to complete
recruitment was described as the main difficulty. One partici-
pant also commented that recruitment at their pharmacy was
limited by a high number of immigrant customers who were
unable to take part because of their limited English language.
Completing the daily recruitment log during the study was
frequently mentioned as a particular problem, mainly because
pharmacy staff forgot to do it. Most staff said they were not
aware of recruited customers having difficulty completing the
questionnaire.
Delivering the intervention did not pose any problems for the
majority of pharmacy staff. Half said that they would ‘definitely’ or
‘quite likely’ continue to deliver the HFHF service if intervention
resources continued, while others mentioned that it would be
dependent on funding. One participant said they would be
unlikely to offer the service due to its time-consuming nature and
small staff numbers. All pharmacies would want to be reimbursed
for continuing to provide the service, and most thought payment
of between £15 and £30 per customer would be required. This
would potentially increase the cost of a future rollout beyond the
cost of pharmacist time considered in the current evaluation
(Table S1). Most also thought that offering the HFHF service from
their pharmacy was beneficial for both customers and the
pharmacy. Pharmacists valued the fact that pharmacy assistants,
as well as pharmacists, were able to deliver the intervention
service.
Semi-structured telephone interviews were conducted with 16
pharmacy intervention customers (seven male, nine female).
When asked what the HFHF service had done for them personally,
most responses referred to the advice they received on
medication use. This included the benefits of trying a different
type of medication, trying a medication that was symptom specific
and medication adherence, for example:
It kick started you back into taking medication regularly. I had
stopped doing it as it wasn’t convenient to get the medication…
Once I started taking medication regularly I was feeling much
better. It’s been revolutionary. (ID068, female, 40s).
She (the pharmacist) told me to try antihistamine and eye
drops. I found these beneficial. You have no idea the difference
this has made. The eye drops have helped enormously. (ID207,
female, 60s).
Customers also mentioned that it had helped raise their
personal awareness and increased their knowledge of how to
manage symptoms of IAR, for example:
The questionnaire made me look at lots of symptoms that I
presumed were caused by asthma. It helped me understand more
about hay fever. (ID033, male, 30s).
Others mentioned the self-help aspect of the intervention, i.e.
applying the personalised practical strategies they had formulated
with the pharmacist/assistant to avoid/minimise hay fever triggers.
These included: drying and washing indoors; changing clothes
after being outside; closing windows when the pollen count was
high; and taking medication before symptoms appeared. Most
participants also felt the length of time spent with pharmacy staff
was about right, although one person felt the pharmacist was
rushed while another said ‘it was a bit long but worthwhile’.
No difficulties were identified with any of the study materials.
Everyone said they would recommend the service to others with
hay fever, and most would be ‘very willing’ to return for a similar
service; only one participant was ‘somewhat willing’ saying there
was no need for further help because his new medication worked.
Most participants would have been willing to pay up to £10 for
the HFHF service they received. Those willing to pay ≥£15 usually
had a high symptom severity score and/or were from a more
affluent area. Six participants were not willing to pay as they either
could not afford it or thought it a service the NHS should provide.
Suggestions on how the service could be improved in a future
trial included: raising awareness that the service was available in
their pharmacy, including through the use of social media; having
uninterrupted time with the pharmacist; and allowing participants
the option to complete data collection forms online to avoid the
need of going to a post box.
DISCUSSION
We conducted the HFHF pilot RCT to assess the transferability of
an Australian community pharmacy IAR intervention to a UK
setting; the methods and measures used in the Australian research
were tested with a view to informing the design of a future RCT.
Our findings suggest that it is feasible to deliver HFHF in the UK.
High participant satisfaction showed that the service was
Table 5. Between-group differences on economic outcome measures.
Outcome Usual care, mean (SD) Intervention, mean (SD) Mean difference (95% CI)a ICC
Total NHS costs (n= 64) £18.78 (17.67) 21.99 (15.30) £2.55 (−£5.77, £10.87) 0.030
Societal costsb (n= 56) £23.72 (18.80) 31.25 (32.15) £7.00 (−£5.84, £19.84) ~0
EQ-5D at 1 week (n= 83) 0.895 (0.181) 0.880 (0.156) −0.010 (−0.080, 0.059) 0.11
EQ-5D at 6 weeks (n= 79) 0.900 (0.178) 0.920 (0.144) 0.019 (−0.044, 0.081) ~0
aAdjusted for pharmacy type and clustering and baseline EQ-5D.
bIncorporates total NHS, patient and indirect productivity costs.
S Smith et al.
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acceptable to customers and pharmacy staff alike; customers all
reported benefits and pharmacists reported benefits for both the
pharmacy and pharmacy staff. The methods employed were
largely acceptable but some of the measures used appeared to
lack sensitivity; future work should review other available
measures. We noted that effect sizes were small, economic
indicators equivocal and retention rates low. However, given the
small scale of the study and the issues concerning the measures
selected, a full trial informed by the findings of this pilot is
warranted. While the cost analysis valued pharmacist time using
standard unit costs, most pharmacists indicated that they would
want to be reimbursed by £15–£30 per patient for providing the
service. Inclusion of such a fee would need to be considered in
future evaluations of cost-effectiveness. However, replacing
pharmacy assistants for pharmacists would reduce the cost of
providing the service.
Response from pharmacies to participate in the study was lower
than expected; a 2001 study monitoring pharmacy customers’ hay
fever symptoms recruited more than half of all pharmacies in
Grampian (64/123)12. The low participation rate in this study may
have been due, in part, to no invitation reminder letter being
issued, as well as other pharmacy service targets taking priority (as
indicated by some declining pharmacies). Previous researchers
have reported that, although pharmacists recognise the impor-
tance of taking part in research, barriers such as lack of time and
support, including financial support, can limit their capacity to
participate27. This is consistent with our qualitative findings where
reimbursement for any future provision of the HFHF service would
be essential.
Study resources were insufficient to allow an investigation of
the fidelity of the intervention as delivered and received. The fact
that pharmacy staff were trained to deliver the intervention is no
guarantee that the intervention was delivered as intended. Studies
of fidelity show that, even after substantial training, adherence to
an intervention protocol can be as low as 43% Hence, a future trial
should also assess the potential for increasing the potency of the
intervention by improving fidelity.
The time of year and weather were significant challenges for
recruitment; delays in obtaining ethics approval meant recruit-
ment started late in the hay fever season, and poor summer
weather (lower temperatures and higher rainfall than usual) led to
lower than usual pollen counts, resulting in lower than expected
numbers of customers with problematic IAR symptoms. This
meant that some pharmacies struggled to reach the recruitment
target of 12 customers.
Although all customers (125) completed a baseline question-
naire at the pharmacy at recruitment, approximately one-third of
the 1-week and 6-week questionnaires were not returned, despite
multiple reminders. Low response rates when using self-
completed postal questionnaires are not unusual in health
services research and pose a significant threat to validity28;
alternative methods for collecting follow-up measures may be
warranted.
The minimal clinically important difference (MCID) for the
miniRQLQ is defined as the smallest change in QOL score that is
meaningful to the patient, but the actual value of the MCID can
vary across studies. For example, in the current study, we used a
value of 0.5 for the miniRQLQ, which was identical to the MCID for
the RQLQ29. Juniper et al. suggested a slightly higher value of 0.7
for the miniRQLQ22, but a later paper by Barnes et al.30 disagreed
with Juniper’s threshold. They pooled miniRQLQ MCIDs from nine
placebo controlled RCTs of intermittent and persistent rhinitis and,
using regression and meta-analytical approaches, estimated the
MCID for the miniRQLQ to be 0.42, which is much closer to the
one we used.
The necessarily small scale of this study had implications for
some of our findings. There was a disparity in SIMD scores
between the two groups at baseline, possibly reflecting the small
numbers of participants. IAR-related QOL improved in both groups
at 1 week, and at 6 weeks this was greater in the intervention
group, albeit a modest difference; if the pilot study had
commenced earlier in the hay fever season, this difference may
have been greater. However, these results only indicate the likely
effect sizes; the small numbers involved in this study provided
insufficient power to assess statistical significance.
IAR-related QOL improved more in the usual care group than
expected. This may be because of a potential Hawthorne effect31,
a phenomenon in which study outcomes are thought to be
influenced by the fact that participants are aware they are being
observed, rather than by the intervention itself. In this case, the
extra time the control group spent with pharmacy staff during the
recruitment process and completing forms relating to their
personal experience of IAR (all of which was over and above
‘usual care’) may have influenced outcomes. Also, keeping a daily
record of symptom severity and medication adherence in the
week after recruitment was a form of self-monitoring, which may
have influenced behaviour32.
Some issues arose concerning the other measures used in this
pilot study. Our measures of medication adherence25, self-
efficacy26 and symptom severity24 revealed no significant
differences between groups. This may have been due to small
numbers of participants or may have been an artefact caused by a
Hawthorne effect. Also, the first two of these measures are not
specifically validated for IAR, which may account for their lack of
sensitivity. Similarly, our results suggest that the EQ-5D may not
be sufficiently sensitive to detect meaningful between-group
differences in IAR-related QOL.
Here we compare our findings to those of the Australian
research15,16. It should be noted, however, that, unlike Smith
et al.15, the current study was a pilot with insufficient statistical
power to detect differences.
AR-related QOL improved significantly in the Australian
studies15,16. The total score for the miniRQLQ mean difference
between groups exceeded the MCID of 0.5 in both studies15,16. In
the first study16, symptom severity also improved significantly.
This study16 showed that participant-reported symptom severity
improved significantly in patients whose goals and strategies were
set by trained pharmacists, compared to patients who set their
own goals and strategies. Self-efficacy was also found to improve
significantly both within and between groups in the second
study15.
Medication adherence was not found to be a significant factor
in either of the Australian studies in terms of behaviour change
and IAR self-management15,16. Although adherence improved in
both groups after 1 week in the current study, there were no
significant differences between groups in change scores. How-
ever, interestingly, adherence was also found not to be a
significant predictor of symptom severity15, whereas AR-related
QOL and strategies to control AR-related triggers was a significant
predictor.
We anticipate that the low pharmacy response rate might be
improved by: issuing reminder letters, promoting the trial via local
pharmacy groups to further encourage involvement, reminding
pharmacists that the training would be continued professional
development for their portfolio, linking the service to existing
extended services such as the Chronic Medication Service
(Scotland) or the Medicines Use Review (rest of UK), providing
appropriate incentives, and digitally augmenting the intervention
through text messaging and/or a dedicated Facebook page. We
might also increase the number of pharmacy assistants trained to
deliver the intervention to reduce demands on pharmacists’ time.
To maximise the pool of potential customer participants,
customer recruitment in any future trial should be conducted at
the start of the hay fever season. In addition, to speed up
recruitment, pharmacies would be required to achieve a certain
percentage of the recruitment within a specific time period or
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otherwise be replaced by another pharmacy. In this way, we
would hope to ameliorate the effects of community pharmacies
achieving particularly slow recruitment rates. One disadvantage of
this approach would be that more pharmacies would need to be
trained as ‘standbys’. However, it is anticipated that staff (and
ultimately the pharmacy) would benefit from the training, even if
they did not participate in the research.
A future trial should place more emphasis on the importance of
returning questionnaires and offer a variety of formats for
completion (e.g. by telephone or electronically), as was suggested
in customer interviews. Edwards28 has noted that financial
incentives to return questionnaires can increase response rates.
In future, the gift voucher given to customer participants to thank
them for taking part may be better delivered on receipt of the
final questionnaire, rather than at recruitment, which might also
improve retention rates.
If the larger-than-expected improvement in outcomes in the
‘usual care’ group was in fact the result of a Hawthorne effect, it
would be important to minimise the level of interaction between
pharmacy staff and study participants. This is a challenging aspect
of the current study design because the processes for recruiting
participants and collecting data necessarily require such interac-
tions. One solution might be to use a Solomon’s design, which
recruits a third group of participants and gives them no measures
to complete except the final primary outcome measures33.
The lack of a clinically important difference in the EQ-5D score
between groups in this pilot suggests that it may not be sensitive
enough to capture the value of improvements in IAR symptoms.
However, failure to detect an important difference may simply
reflect the small numbers and/or unexpected improvements in
the control arm of the trial. While use of the EQ-5D (or another
similar but potentially more sensitive generic instrument) should
be retained in any future trial, a future economic evaluation could
also include some primary preference elicitation work to assess
the value that patients or the public place on IAR-specific
improvements in health-related QOL (HRQOL).
Our findings suggest that the HFHF service, delivered in Scottish
community pharmacies, is feasible to deliver and acceptable to
customers and pharmacy staff and may have the potential to
improve IAR management. This pilot study has derived data on
estimates of effect sizes, participation rates and completion rates,
which can be used to inform a future RCT. Based on these data, we
have proposed modifications to pharmacy and customer recruit-
ment procedures, measurement procedures and instruments and
have suggested ways to maximise retention rates.
The economic analysis undertaken in this pilot work suggests
that the intervention may increase costs to the NHS, particularly if
it requires a fee for service, and may result in a small improvement
in general HRQOL at 6 weeks. Longer-term follow-up in a
definitive trial is required to ascertain whether any differences
are real and sustainable. Cost-effectiveness of a future trial from an
NHS perspective will likely depend on the price at which
pharmacists are willing to supply the service and the extent to
which pharmacy assistants can substitute for pharmacists, as well
as the clinical significance and durability of any observed
improvements in HRQOL. From a societal perspective, costs may
also be offset by potential improvements in workplace
performance.
A full RCT is now needed to determine whether the clinical
benefits suggested by this pilot can be replicated, or even
enhanced, on a larger scale. If findings from the full trial indicate
that the HFHF intervention is a cost-effective way to help
individuals better manage their seasonal IAR, this goal-focussed,
behaviour change intervention could be rolled out to all
community pharmacies.
METHODS
The protocol for this pilot trial is published elsewhere34. A summary of
methods is presented here. Changes to the original protocol are listed in
Supplementary Note 3.
Study design
This was a community pharmacy-based pilot cluster RCT of a goal-focussed
self-management intervention for IAR with associated economic analysis
and a qualitative evaluation of the acceptability, experiences of and
satisfaction with the intervention and acceptability of the measures used.
The trial was conducted in two Scottish HBAs: (1) Grampian and (2) Greater
Glasgow and Clyde. Recruited pharmacies (clusters) were randomised to
deliver the HFHF intervention or to deliver ‘usual care’ to customers with
IAR. Trained pharmacy staff recruited and consented eligible pharmacy
customers using pre-specified inclusion/exclusion criteria (see below).
Ethical approvals were obtained from the North of Scotland committee of
the National Research Ethics Service (NRES) in May 2012, prior to
commencing the research.
Recruitment
Our target was to recruit 12 community pharmacies, 6 in each HBA. All
community pharmacies in both HBAs (n= 445) were invited by letter to
participate in the study. No reminders were sent. Consenting pharmacies
were stratified by location and by pharmacy status (independent/small
multiple/national multiple) and were randomised to intervention or usual
care34. Pharmacies that consented but not included were informed of this
by letter and asked if they would be willing to be on ‘stand by’ should any
of the selected pharmacies drop out.
Pharmacy staff in both intervention and usual care groups received
training in recruitment and written informed consent of study customers.
Staff from intervention pharmacies attended a 3-h training event about
IAR, its management17 and delivery of the intervention34; this included
‘role play’ where attendees worked in pairs to practise receiving and
delivering the intervention.
Knowledge of IAR and its management was assessed before and straight
after training using a knowledge-based multiple-choice questionnaire. For
the purpose of informing training in a future RCT, staff satisfaction with,
and acceptability of, the training were evaluated immediately after the
event using a questionnaire adapted from one used previously in the
Australian study35.
Customer recruitment began at the end of June 2012 for 4 months. In all
pharmacies, potential participants were identified when they asked for
advice about IAR symptoms, or requested medication for IAR, or presented
a prescription for IAR medication. All willing participants completed an
eligibility checklist before recruitment. Inclusion criteria were: being >18
years of age; having a history of IAR; having active symptoms of
intermittent IAR as defined by ARIA (Allergic Rhinitis and its Impact on
Asthma) guidelines36; being able to speak, write and understand English.
Exclusion criteria were: being pregnant; having a terminal illness; having
symptoms not suggestive of IAR; having taken part in an allergic rhinitis
study within the past 2 years. Each pharmacy was asked to record daily
recruitment data, thus providing a number log of customers who were
ineligible, recruited or declined to participate.
The HFHF intervention
The intervention was based on an Australian study14–16. To enhance its
replicability, components of the intervention were specified37 using a
validated taxonomy of behaviour change techniques38. Eligible customers
received the intervention, delivered in one session by intervention
pharmacy staff34. Customers were counselled on IAR management and
treatment and provided with a card containing two pre-determined goals:
● to avoid/minimise hay fever triggers
● to eliminate/minimise hay fever symptoms.
In this card, participants wrote down their personal IAR triggers and
symptoms, and pharmacy staff supported them in formulating persona-
lised action plans for achieving the two goals. The purpose of this card was
to engage customers in the self-management of their IAR; personally
selected health-related goals are more likely to lead to positive changes in
illness-related behaviour39. Participants also received printed information
about IAR symptoms, triggers and other general IAR information.
Customers from non-intervention pharmacies received usual care.
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Data collection
The baseline questionnaire was used to collect data about participants’
current experience of IAR including: IAR-related QOL (validated miniRQLQ
—see Supplementary Note 4)22, generic health status (EQ-5D)40, symptom
severity24, Work Productivity and Activity Impairment (WPAI)41, medication
adherence25, and self-efficacy with respect to IAR management26.
Participating customers in both groups were given a record card to
complete daily in the week following recruitment; on this card they
recorded a symptom severity score and adherence to IAR medication. All
participants were mailed a second questionnaire (identical to baseline)
1 week after recruitment, and 6 weeks after recruitment they were mailed
a third questionnaire to collect some outcome data (miniRQLQ, EQ-5D,
WPAI)34 and additional data for economic analysis of any future RCT.
Participants who had not returned their 1- or 6-week questionnaire
2 weeks after they were sent out received a reminder by telephone or
email34. The 6-week questionnaire was sent to participants even though
they did not return their 1-week questionnaire.
Semi-structured interviews with intervention pharmacists and a
purposive sample of intervention customers (selected to represent a
range of gender, age and symptom severity) were conducted to elicit
views on experiences of and satisfaction with the intervention and the trial
methods. Interview schedules were informed by the findings of the
Australian research35.
Outcome measures
The outcome measures were: community pharmacy and pharmacy
customer recruitment; retention and completion rates; effect size and
variability of change in IAR-related QOL (assessed by the miniRQLQ)
between baseline, 1 week and 6 weeks. The miniRQLQ comprises four
domains with three items and one with two items measuring, on a 0–6
response scale, the impact of IAR symptoms on QOL: activities, practical
problems, nose symptoms, eye symptoms, and other symptoms. Mean
scores are calculated for each domain and a total score for all 14 items. We
considered a decrease of 0.5 in mean total score to be a clinically relevant
improvement.
Other outcomes were: symptom severity, medication adherence and
self-efficacy (i.e. belief in one’s ability to succeed in specific situations or
accomplish a task)42 and acceptability of and satisfaction with study
components (community pharmacy staff and pharmacy customers).
Pharmacy consultation time was costed for all participants using a
published cost per-hour of community pharmacist time43. Medications
either prescribed by pharmacists or obtained through the Minor Ailments
Scheme at the initial consultation were valued using the British National
Formulary (BNF) list price44, while those purchased over-the-counter were
costed at their retail price. Data on use of health services over the follow-
up period were estimated from patient questionnaires administered
6 weeks post-randomisation, as was overall use of prescribed and over-the-
counter medications (type and quantity). Health service consultations were
costed using unit costs derived from routine sources43, and medications
were costed using BNF list prices or purchase prices as appropriate. The
WPAI questionnaire was tested 1 week post-randomisation and any
reported time lost from work was valued using age/sex-specific average
gross wage rates45. Total NHS costs and broader societal costs
(incorporating patient out-of-pocket medication costs and indirect costs
of lost production) were then estimated per patient based on the
components described above.
Sample size
As this was a pilot RCT, no formal sample size calculation was
undertaken46; however, sufficient numbers were required to estimate
effect sizes and give a reliable ICC to inform a future full evaluation. We
aimed to retain 10 pharmacies (5 per study arm) with 10 patients in each
pharmacy. Therefore, to allow for attrition, our initial target recruitment
was 12 pharmacies each recruiting 12 customers (i.e. total sample size of
144 patients).
Data management and analysis
Data were entered into SPSS (version 20) and analysed using Stata version
14 (StataCorp LP, College Station, TX, USA). For descriptive analysis, mean
(SD) miniRQLQ total scores across each timepoint were summarised by
randomisation group for all participants and for complete cases (as a
sensitivity analysis). A multi-level, mixed-effect linear regression model was
applied using the ‘xtmixed’ command to fit linear mixed models for the
miniRQLQ and its subscales. The model was used to determine the
treatment effect (i.e. the difference in 6-week miniRQLQ score between the
intervention and usual care group, adjusted for clustering by pharmacy).
We reported results based on all participants as well as a complete case
sensitivity analysis. It should be noted, however, that, since this was a pilot
study, it is recognised that formal statistical analysis is underpowered and
effects should be interpreted as descriptive.
Analysis of the economic outcomes adopted the same approach as used
for the miniRQLQ and focussed on estimating differences in costs to the
NHS (incorporating intervention and follow-up costs) and costs to society
(incorporating patient and indirect costs) at 6 weeks, and differences in EQ-
5D score at 1 week and 6 weeks (adjusted for clustering, pharmacy type
and baseline EQ-5D score). Given the small numbers and short-term nature
of this exploratory pilot study, we do not report a full incremental cost-
effectiveness analysis.
One researcher (S.S.) carried out thematic descriptive analysis of the
qualitative data. Interpretation and allocation of themes were discussed
and cross-checked by a co-author (L.S.) to minimise potential
researcher bias.
This pilot cluster RCT has followed the CONSORT 2010 checklist of
information to include when reporting a pilot or feasibility trial
(Supplementary Note 5).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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